Jaume Mora

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/11496/publications.pdf

Version: 2024-02-01

170 papers	17,895 citations	44069 48 h-index	14759 127 g-index
173 all docs	173 docs citations	173 times ranked	27827 citing authors

#	Article	IF	Citations
1	Mutational heterogeneity in cancer and the search for new cancer-associated genes. Nature, 2013, 499, 214-218.	27.8	4,761
2	Inactivation of the apoptosis effector Apaf-1 in malignant melanoma. Nature, 2001, 409, 207-211.	27.8	901
3	Intertumoral Heterogeneity within Medulloblastoma Subgroups. Cancer Cell, 2017, 31, 737-754.e6.	16.8	836
4	The whole-genome landscape of medulloblastoma subtypes. Nature, 2017, 547, 311-317.	27.8	787
5	Integrated Molecular Meta-Analysis of 1,000 Pediatric High-Grade and Diffuse Intrinsic Pontine Glioma. Cancer Cell, 2017, 32, 520-537.e5.	16.8	716
6	Comprehensive Genomic Analysis of Rhabdomyosarcoma Reveals a Landscape of Alterations Affecting a Common Genetic Axis in Fusion-Positive and Fusion-Negative Tumors. Cancer Discovery, 2014, 4, 216-231.	9.4	596
7	Developmental and oncogenic programs in H3K27M gliomas dissected by single-cell RNA-seq. Science, 2018, 360, 331-335.	12.6	461
8	High TGFÎ²-Smad Activity Confers Poor Prognosis in Glioma Patients and Promotes Cell Proliferation Depending on the Methylation of the PDGF-B Gene. Cancer Cell, 2007, 11, 147-160.	16.8	446
9	Atypical Teratoid/Rhabdoid Tumors Are Comprised of Three Epigenetic Subgroups with Distinct Enhancer Landscapes. Cancer Cell, 2016, 29, 379-393.	16.8	438
10	Recurrent activating ACVR1 mutations in diffuse intrinsic pontine glioma. Nature Genetics, 2014, 46, 457-461.	21.4	423
11	The Genomic Landscape of Pediatric Ewing Sarcoma. Cancer Discovery, 2014, 4, 1326-1341.	9.4	415
12	EZH2 is a potential therapeutic target for H3K27M-mutant pediatric gliomas. Nature Medicine, 2017, 23, 483-492.	30.7	392
13	Complementary genomic approaches highlight the PI3K/mTOR pathway as a common vulnerability in osteosarcoma. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E5564-73.	7.1	355
14	A remarkably simple genome underlies highly malignant pediatric rhabdoid cancers. Journal of Clinical Investigation, 2012, 122, 2983-2988.	8.2	347
15	Recurrence patterns across medulloblastoma subgroups: an integrated clinical and molecular analysis. Lancet Oncology, The, 2013, 14, 1200-1207.	10.7	307
16	Prognostic value of medulloblastoma extent of resection after accounting for molecular subgroup: a retrospective integrated clinical and molecular analysis. Lancet Oncology, The, 2016, 17, 484-495.	10.7	274
17	Cytogenetic Prognostication Within Medulloblastoma Subgroups. Journal of Clinical Oncology, 2014, 32, 886-896.	1.6	263
18	Sarcoma classification by DNA methylation profiling. Nature Communications, 2021, 12, 498.	12.8	237

#	Article	IF	Citations
19	Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. Journal of Clinical Oncology, 2016, 34, 2468-2477.	1.6	160
20	EMP3, a Myelin-Related Gene Located in the Critical 19q13.3 Region, Is Epigenetically Silenced and Exhibits Features of a Candidate Tumor Suppressor in Glioma and Neuroblastoma. Cancer Research, 2005, 65, 2565-2571.	0.9	154
21	TERT promoter mutations are highly recurrent in SHH subgroup medulloblastoma. Acta Neuropathologica, 2013, 126, 917-929.	7.7	146
22	Functional diversity and cooperativity between subclonal populations of pediatric glioblastoma and diffuse intrinsic pontine glioma cells. Nature Medicine, 2018, 24, 1204-1215.	30.7	133
23	Activating mutations in CSF1R and additional receptor tyrosine kinases in histiocytic neoplasms. Nature Medicine, 2019, 25, 1839-1842.	30.7	122
24	Molecularly defined diffuse leptomeningeal glioneuronal tumor (DLGNT) comprises two subgroups with distinct clinical and genetic features. Acta Neuropathologica, 2018, 136, 239-253.	7.7	118
25	EWS/FLI Confers Tumor Cell Synthetic Lethality to CDK12 Inhibition in Ewing Sarcoma. Cancer Cell, 2018, 33, 202-216.e6.	16.8	116
26	N7: A novel multi-modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	114
27	Epigenetic loss of RNA-methyltransferase NSUN5 in glioma targets ribosomes to drive a stress adaptive translational program. Acta Neuropathologica, 2019, 138, 1053-1074.	7.7	106
28	Riskâ€“benefit of dexrazoxane for preventing anthracycline-related cardiotoxicity: re-evaluating the European labeling. Future Oncology, 2018, 14, 2663-2676.	2.4	105
29	Primary intracranial spindle cell sarcoma with rhabdomyosarcoma-like features share a highly distinct methylation profile and DICER1 mutations. Acta Neuropathologica, 2018, 136, 327-337.	7.7	104
30	Accurate Outcome Prediction in Neuroblastoma across Independent Data Sets Using a Multigene Signature. Clinical Cancer Research, 2010, 16, 1532-1541.	7.0	86
31	Heterogeneity within the PF-EPN-B ependymoma subgroup. Acta Neuropathologica, 2018, 136, 227-237.	7.7	86
32	Exome and deep sequencing of clinically aggressive neuroblastoma reveal somatic mutations that affect key pathways involved in cancer progression. Oncotarget, 2016, 7, 21840-21852.	1.8	85
33	Long noncoding RNA EWSAT1-mediated gene repression facilitates Ewing sarcoma oncogenesis. Journal of Clinical Investigation, 2014, 124, 5275-5290.	8.2	81
34	Neuroblastic and Schwannian stromal cells of neuroblastoma are derived from a tumoral progenitor cell. Cancer Research, 2001, 61, 6892-8.	0.9	79
35	The PARP inhibitor olaparib enhances the sensitivity of Ewing sarcoma to trabectedin. Oncotarget, 2015, 6, 18875-18890.	1.8	74
36	Treatment of Relapsed/Refractory Pediatric Sarcomas With Gemcitabine and Docetaxel. Journal of Pediatric Hematology/Oncology, 2009, 31, 723-729.	0.6	73

#	Article	IF	Citations
37	ALK2 inhibitors display beneficial effects in preclinical models of ACVR1 mutant diffuse intrinsic pontine glioma. Communications Biology, 2019, 2, 156.	4.4	73
38	A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 1343-1357.	7.0	69
39	Lymphoblastic lymphoma of childhood and the LSA2-L2 protocol. Cancer, 2003, 98, 1283-1291.	4.1	67
40	Therapeutic targeting of the RB1 pathway in retinoblastoma with the oncolytic adenovirus VCN-01. Science Translational Medicine, 2019, 11, .	12.4	67
41	Wilms tumor cells with WT1 mutations have characteristic features of mesenchymal stem cells and express molecular markers of paraxial mesoderm. Human Molecular Genetics, 2010, 19, 1651-1668.	2.9	66
42	Genome-wide analysis of gene expression associated with MYCN in human neuroblastoma. Cancer Research, 2003, 63, 4538-46.	0.9	65
43	In vivo CRISPR/Cas9 targeting of fusion oncogenes for selective elimination of cancer cells. Nature Communications, 2020, 11, 5060.	12.8	60
44	A Three-Gene Expression Signature Model for Risk Stratification of Patients with Neuroblastoma. Clinical Cancer Research, 2012, 18, 2012-2023.	7.0	59
45	DNA methylation-based reclassification of olfactory neuroblastoma. Acta Neuropathologica, 2018, 136, 255-271.	7.7	59
46	Expression of the neuron-specific protein CHD5 is an independent marker of outcome in neuroblastoma. Molecular Cancer, 2010, 9, 277.	19.2	57
47	The second European interdisciplinary Ewing sarcoma research summit - A joint effort to deconstructing the multiple layers of a complex disease. Oncotarget, 2016, 7, 8613-8624.	1.8	55
48	Comprehensive characterization of neuroblastoma cell line subtypes reveals bilineage potential similar to neural crest stem cells. BMC Developmental Biology, 2009, 9, 12.	2.1	54
49	Large cell non-Hodgkin lymphoma of childhood. , 2000, 88, 186-197.		49
50	Use of 3D Prototypes for Complex Surgical Oncologic Cases. World Journal of Surgery, 2016, 40, 889-894.	1.6	49
51	Therapeutic Targeting of KDM1A/LSD1 in Ewing Sarcoma with SP-2509 Engages the Endoplasmic Reticulum Stress Response. Molecular Cancer Therapeutics, 2018, 17, 1902-1916.	4.1	48
52	The transcriptional landscape of Shh medulloblastoma. Nature Communications, 2021, 12, 1749.	12.8	47
53	Clinical Categories of Neuroblastoma Are Associated with Different Patterns of Loss of Heterozygosity on Chromosome Arm 1p. Journal of Molecular Diagnostics, 2000, 2, 37-46.	2.8	46
54	Gemcitabine plus sirolimus for relapsed and progressing osteosarcoma patients after standard chemotherapy: a multicenter, single-arm phase II trial of Spanish Group for Research on Sarcoma (GEIS). Annals of Oncology, 2017, 28, 2994-2999.	1.2	45

#	Article	IF	Citations
55	A high-risk retinoblastoma subtype with stemness features, dedifferentiated cone states and neuronal/ganglion cell gene expression. Nature Communications, 2021, 12, 5578.	12.8	45
56	Genetics of pheochromocytoma and paraganglioma in Spanish pediatric patients. Endocrine-Related Cancer, 2013, 20, L1-L6.	3.1	44
57	DNA Methylomes Reveal Biological Networks Involved in Human Eye Development, Functions and Associated Disorders. Scientific Reports, 2017, 7, 11762.	3.3	44
58	Preclinical Efficacy of Endoglin-Targeting Antibodyâ€“Drug Conjugates for the Treatment of Ewing Sarcoma. Clinical Cancer Research, 2019, 25, 2228-2240.	7.0	44
59	Loss of heterozygosity at 19q13.3 is associated with locally aggressive neuroblastoma. Clinical Cancer Research, 2001, 7, 1358-61.	7.0	42
60	DNA methylation fingerprint of neuroblastoma reveals new biological and clinical insights. Epigenomics, 2015, 7, 1137-1153.	2.1	40
61	SN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgery. Biomaterials, 2016, 79, 69-78.	11.4	40
62	Desmoplastic small round cell tumor 20 years after its discovery. Future Oncology, 2015, 11, 1071-1081.	2.4	39
63	Dinutuximab for the treatment of pediatric patients with high-risk neuroblastoma. Expert Review of Clinical Pharmacology, 2016, 9, 647-653.	3.1	39
64	Primary epidural non-Hodgkin lymphoma: Spinal cord compression syndrome as the initial form of presentation in childhood non-Hodgkin lymphoma. , 1999, 32, 102-105.		35
65	The calcium-sensing receptor is silenced by genetic and epigenetic mechanisms in unfavorable neuroblastomas and its reactivation induces ERK1/2-dependent apoptosis. Carcinogenesis, 2013, 34, 268-276.	2.8	35
66	Targeted drug distribution in tumor extracellular fluid of GD2-expressing neuroblastoma patient-derived xenografts using SN-38-loaded nanoparticles conjugated to the monoclonal antibody 3F8. Journal of Controlled Release, 2017, 255, 108-119.	9.9	35
67	EphA2 receptor is a key player in the metastatic onset of Ewing sarcoma. International Journal of Cancer, 2018, 143, 1188-1201.	5.1	35
68	NG2 antigen is involved in leukemia invasiveness and central nervous system infiltration in MLL-rearranged infant B-ALL. Leukemia, 2018, 32, 633-644.	7.2	35
69	Subgroup and subtype-specific outcomes in adult medulloblastoma. Acta Neuropathologica, 2021, 142, 859-871.	7.7	34
70	EphA2-Induced Angiogenesis in Ewing Sarcoma Cells Works through bFGF Production and Is Dependent on Caveolin-1. PLoS ONE, 2013, 8, e71449.	2.5	34
71	Genetic heterogeneity and clonal evolution in neuroblastoma. British Journal of Cancer, 2001, 85, 182-189.	6.4	32
72	DNA Hypomethylation Affects Cancer-Related Biological Functions and Genes Relevant in Neuroblastoma Pathogenesis. PLoS ONE, 2012, 7, e48401.	2.5	31

#	Article	IF	Citations
73	Immune Response Generated With the Administration of Autologous Dendritic Cells Pulsed With an Allogenic Tumoral Cell-Lines Lysate in Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma. Frontiers in Oncology, 2018, 8, 127.	2.8	31
74	Positional gene expression analysis identifies 12q overexpression and amplification in a subset of neuroblastomas. Cancer Genetics and Cytogenetics, 2004, 154, 131-137.	1.0	30
75	Evolving significance of prognostic markers associated with treatment improvement in patients with Stage 4 neuroblastoma. Cancer, 2002, 94, 2756-2765.	4.1	28
76	Brain stem tumors in children and adolescents: single institutional experience. Child's Nervous System, 2013, 29, 1321-1331.	1.1	28
77	Clinicopathologic and molecular analysis of embryonal rhabdomyosarcoma of the genitourinary tract: evidence for a distinct DICER1-associated subgroup. Modern Pathology, 2021, 34, 1558-1569.	5.5	28
78	Primary Ewing sarcoma of the tentorium presenting with intracranial hemorrhage in a child. Journal of Neurosurgery: Pediatrics, 2007, 107, 411-415.	1.3	27
79	Intraâ€arterial chemotherapy for retinoblastoma. Challenges of a prospective study. Acta Ophthalmologica, 2014, 92, 209-215.	1.1	27
80	Glucosylated nanomicelles target glucose-avid pediatric patient-derived sarcomas. Journal of Controlled Release, 2018, 276, 59-71.	9.9	27
81	The combination of epigenetic drugs SAHA and HCI-2509 synergistically inhibits EWS-FLI1 and tumor growth in Ewing sarcoma. Oncotarget, 2018, 9, 31397-31410.	1.8	27
82	Specific gene expression profiles and chromosomal abnormalities are associated with infant disseminated neuroblastoma. BMC Cancer, 2009, 9, 44.	2.6	26
83	Activated growth signaling pathway expression in Ewing sarcoma and clinical outcome. Pediatric Blood and Cancer, 2012, 58, 532-538.	1.5	26
84	Evolving significance of prognostic markers associated with new treatment strategies in neuroblastoma. Cancer Letters, 2003, 197, 119-124.	7.2	25
85	Origin of neuroblastic tumors: clues for future therapeutics. Expert Review of Molecular Diagnostics, 2004, 4, 293-302.	3.1	25
86	Different CTNNB1 mutations as molecular genetic proof for the independent origin of four Wilms tumours in a patient with a novel germ line WT1 mutation. Journal of Medical Genetics, 2007, 44, 393-396.	3.2	25
87	DNA methylation profiling identifies PTRF/Cavin-1 as a novel tumor suppressor in Ewing sarcoma when co-expressed with caveolin-1. Cancer Letters, 2017, 386, 196-207.	7.2	25
88	Successful treatment of childhood intramedullary spinal cord astrocytomas with irinotecan and cisplatin. Neuro-Oncology, 2007, 9, 39-46.	1.2	24
89	A Novel Method for Rapid Molecular Subgrouping of Medulloblastoma. Clinical Cancer Research, 2018, 24, 1355-1363.	7.0	24
90	RING1B recruits EWSR1-FLI1 and cooperates in the remodeling of chromatin necessary for Ewing sarcoma tumorigenesis. Science Advances, 2020, 6, .	10.3	24

#	Article	IF	Citations
91	Pattern of Relapse and Treatment Response in WNT-Activated Medulloblastoma. Cell Reports Medicine, 2020, 1, 100038.	6.5	24
92	Spontaneous remission of congenital acute nonlymphoblastic leukemia with normal karyotype in twins. Medical and Pediatric Oncology, 2000, 35, 110-113.	1.0	23
93	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer, 2001, 91, 435-442.	4.1	23
94	The calciumâ€sensing receptor and parathyroid hormoneâ€related protein are expressed in differentiated, favorable neuroblastic tumors. Cancer, 2009, 115, 2792-2803.	4.1	23
95	Preclinical platform of retinoblastoma xenografts recapitulating human disease and molecular markers of dissemination. Cancer Letters, 2016, 380, 10-19.	7.2	22
96	Transverse myelitis as an unexpected complication following treatment with dinutuximab in pediatric patients with highâ€risk neuroblastoma: A case series. Pediatric Blood and Cancer, 2018, 65, e26732.	1.5	21
97	Naxitamab combined with granulocyteâ€macrophage colonyâ€stimulating factor as consolidation for highâ€risk neuroblastoma patients in complete remission. Pediatric Blood and Cancer, 2021, 68, e29121.	1.5	21
98	Pediatric paraganglioma: An early manifestation of an adult disease secondary to germline mutations. Pediatric Blood and Cancer, 2006, 47, 785-789.	1.5	20
99	Antiangiogenic treatment as a preâ€operative management of alveolar softâ€part sarcoma. Pediatric Blood and Cancer, 2011, 57, 1071-1073.	1.5	20
100	LIN28B Underlies the Pathogenesis of a Subclass of Ewing Sarcoma. Cell Reports, 2020, 30, 4567-4583.e5.	6.4	20
101	Caveolin-1 is down-regulated in alveolar rhabdomyosarcomas and negatively regulates tumor growth. Oncotarget, 2014, 5, 9744-9755.	1.8	19
102	Cinacalcet inhibits neuroblastoma tumor growth and upregulates cancer-testis antigens. Oncotarget, 2016, 7, 16112-16129.	1.8	19
103	The onset of PI3Kâ€related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib. EMBO Molecular Medicine, 2022, 14, .	6.9	19
104	Epstein-Barr virus related opsoclonus-myoclonus-ataxia does not rule out the presence of occult neuroblastic tumors. Pediatric Blood and Cancer, 2006, 47, 964-967.	1.5	17
105	GEIS-21: a multicentric phase II study of intensive chemotherapy including gemcitabine and docetaxel for the treatment of Ewing sarcoma of children and adults: a report from the Spanish sarcoma group (GEIS). British Journal of Cancer, 2017, 117, 767-774.	6.4	17
106	The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies. Frontiers in Pharmacology, 2020, 11, 575009.	3.5	17
107	Novel regions of allelic imbalance identified by genome-wide analysis of neuroblastoma. Cancer Research, 2002, 62, 1761-7.	0.9	17
108	Use of angioembolization as an effective technique for the management of pediatric solid tumors. Journal of Pediatric Surgery, 2009, 44, 1848-1855.	1.6	16

#	Article	IF	Citations
109	Molecular Genetics of Neuroblastoma and the Implications for Clinical Management: A Review of the MSKCC Experience. Oncologist, 2001, 6, 263-268.	3.7	15
110	Results of induction chemotherapy in children older than 18Âmonths with stage-4 neuroblastoma treated with an adaptive-to-response modified N7 protocol (mN7). Clinical and Translational Oncology, 2015, 17, 521-529.	2.4	14
111	Second re-irradiation for DIPG progression, re-considering â€œold strategiesâ€•with new approaches. Child's Nervous System, 2017, 33, 849-852.	1.1	14
112	Listeriosis in pediatric oncology patients. , 1998, 83, 817-820.		13
113	Polymorphisms in the Calcium-Sensing Receptor Gene Are Associated with Clinical Outcome of Neuroblastoma. PLoS ONE, 2013, 8, e59762.	2.5	13
114	Comprehensive analysis of the 9p21 region in neuroblastoma suggests a role for genes mapping to 9p21â€“23 in the biology of favourable stage 4 tumours. British Journal of Cancer, 2004, 91, 1112-1118.	6.4	12
115	Treatment of Ewing sarcoma family of tumors with a modified P6 protocol in children and adolescents. Pediatric Blood and Cancer, 2011, 57, 69-75.	1.5	12
116	RING1B contributes to Ewing sarcoma development by repressing the NaV1.6 sodium channel and the NF-Î°B pathway, independently of the fusion oncoprotein. Oncotarget, 2016, 7, 46283-46300.	1.8	12
117	SPARC-mediated long-term retention of nab-paclitaxel in pediatric sarcomas. Journal of Controlled Release, 2022, 342, 81-92.	9.9	12
118	Laser-capture microdissected Schwannian and neuroblastic cells in stage 4 neuroblastomas have the same genetic alterations. Medical and Pediatric Oncology, 2000, 35, 534-537.	1.0	11
119	Epithelioid sarcoma with SYT-SSX1 fusion gene expression: molecular and cytogenetic analysis. Cancer Genetics and Cytogenetics, 2005, 162, 50-56.	1.0	11
120	Combined Microdialysis-Tumor Homogenate Method for the Study of the Steady State Compartmental Distribution of a Hydrophobic Anticancer Drug in Patient-Derived Xenografts. Pharmaceutical Research, 2015, 32, 2889-2900.	3.5	11
121	Safety of bevacizumab in patients younger than 4 years of age. Clinical and Translational Oncology, 2016, 18, 464-468.	2.4	11
122	Genetic variants in the promoter region of the calciumâ€sensing receptor gene are associated with its downâ€regulation in neuroblastic tumors. Molecular Carcinogenesis, 2017, 56, 1281-1289.	2.7	11
123	Increased delivery of chemotherapy to the vitreous by inhibition of the blood-retinal barrier. Journal of Controlled Release, 2017, 264, 34-44.	9.9	11
124	Chemotherapy and terminal skeletal muscle differentiation in <scp>WT</scp>1â€mutant Wilms tumors. Cancer Medicine, 2018, 7, 1359-1368.	2.8	11
125	Comprehensive analysis of tumoral DNA content reveals clonal ploidy heterogeneity as a marker with prognostic significance in locoregional neuroblastoma. Genes Chromosomes and Cancer, 2007, 46, 385-396.	2.8	10
126	Treatment of disseminated paraganglioma with gemcitabine and docetaxel. Pediatric Blood and Cancer, 2009, 53, 663-665.	1.5	10

#	Article	IF	Citations
127	Low-grade gliomas in children: single institutional experience in 198 cases. Child's Nervous System, 2015, 31, 1447-1459.	1.1	10
128	Establishment of a Conditionally Immortalized Wilms Tumor Cell Line with a Homozygous WT1 Deletion within a Heterozygous 11p13 Deletion and UPD Limited to 11p15. PLoS ONE, 2016, 11, e0155561.	2.5	10
129	Prognostic value of patientâ€derived xenograft engraftment in pediatric sarcomas. Journal of Pathology: Clinical Research, 2021, 7, 338-349.	3.0	10
130	Selective inhibition of HDAC6 regulates expression of the oncogenic driver EWSR1-FLI1 through the EWSR1 promoter in Ewing sarcoma. Oncogene, 2021, 40, 5843-5853.	5.9	10
131	Comprehensive Biology and Genetics Compendium of Wilms Tumor Cell Lines with Different WT1 Mutations. Cancers, 2021, 13, 60.	3.7	10
132	Selective histone methyltransferase G9a inhibition reduces metastatic development of Ewing sarcoma through the epigenetic regulation of NEU1. Oncogene, 2022, 41, 2638-2650.	5.9	10
133	Differential expression of genes mapping to recurrently abnormal chromosomal regions characterize neuroblastic tumours with distinct ploidy status. BMC Medical Genomics, 2008, 1, 36.	1.5	9
134	Fibrolamellar Hepatocellular Carcinoma in an Infant and Literature Review. Journal of Pediatric Hematology/Oncology, 2008, 30, 968-971.	0.6	9
135	Identification of tumoral glial precursor cells in neuroblastoma. Cancer Letters, 2011, 312, 73-81.	7.2	9
136	Recurrent Somatic Chromosomal Abnormalities in Relapsed Extraocular Retinoblastoma. Cancers, 2021, 13, 673.	3.7	9
137	Outpatient administration of naxitamab in combination with granulocyteâ€macrophage colonyâ€stimulating factor in patients with refractory and/or relapsed highâ€risk neuroblastoma: Management of adverse events. Cancer Reports, 2023, 6, e1627.	1.4	9
138	Parathyroid hormoneâ€like hormone plays a dual role in neuroblastoma depending on <scp>PTH</scp>1R expression. Molecular Oncology, 2019, 13, 1959-1975.	4.6	8
139	Simultaneous <scp>KIT</scp> mutation and succinate dehydrogenase (<scp>SDH</scp>) deficiency in a patient with a gastrointestinal stromal tumour and Carneyâ€Stratakis syndrome: a case report. Histopathology, 2014, 65, 712-717.	2.9	7
140	Orphan drugs revisited: costâ€“effectiveness analysis of the addition of mifamurtide to the conventional treatment of osteosarcoma. Expert Review of Pharmacoeconomics and Outcomes Research, 2015, 15, 331-340.	1.4	7
141	Treatment-driven selection of chemoresistant Ewing sarcoma tumors with limited drug distribution. Journal of Controlled Release, 2020, 324, 440-449.	9.9	7
142	Nivolumab in paediatric cancer: children are not little adults. Lancet Oncology, The, 2020, 21, 474-476.	10.7	7
143	Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma. Cancers, 2021, 13, 1264.	3.7	7
144	Autologous Stem-Cell Transplantation for High-Risk Neuroblastoma: Historical and Critical Review. Cancers, 2022, 14, 2572.	3.7	7

#	Article	IF	Citations
145	Axenfeldâ€“Rieger ocular anomaly and retinoblastoma caused by constitutional chromosome 13q deletion. Pediatric Blood and Cancer, 2010, 54, 480-482.	1.5	6
146	What is a pediatric tumor?. Clinical Oncology in Adolescents and Young Adults, 2012, , 7.	0.8	6
147	Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Preliminary results of HITS pilot/phase II study.. Journal of Clinical Oncology, 2019, 37, 10025-10025.	1.6	6
148	Burkitt's lymphoma treatment in a rural hospital in Sierra Leone. Transactions of the Royal Society of Tropical Medicine and Hygiene, 2013, 107, 653-659.	1.8	5
149	Tissue Compatibility of SNâ€38â€Loaded Anticancer Nanofiber Matrices. Advanced Healthcare Materials, 2018, 7, e1800255.	7.6	5
150	How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de DÃ©u in Barcelona, Spain. ESMO Open, 2022, 7, 100462.	4.5	5
151	MIF/CXCR4 signaling axis contributes to survival, invasion, and drug resistance of metastatic neuroblastoma cells in the bone marrow microenvironment. BMC Cancer, 2022, 22, .	2.6	5
152	Landscape of early clinical trials for childhood and adolescence cancer in Spain. Clinical and Translational Oncology, 2016, 18, 708-713.	2.4	4
153	WT1-Mutant Wilms Tumor Progression Is Associated With Diverting Clonal Mutations of CTNNB1. Journal of Pediatric Hematology/Oncology, 2021, 43, e180-e183.	0.6	4
154	Neural crest derived progenitor cells contribute to tumor stroma and aggressiveness in stage 4/M neuroblastoma. Oncotarget, 2017, 8, 89775-89792.	1.8	4
155	Survival analysis of clinical, pathologic, and genetic features in neuroblastoma presenting as locoregional disease. Cancer, 2001, 91, 435-42.	4.1	4
156	Primitive hematopoietic malignant neoplasm presenting as a CD43-positive, small round, blue-cell tumor in an infant. Pediatric Blood and Cancer, 2005, 45, 865-866.	1.5	3
157	Treatment of childhood astrocytomas with irinotecan and cisplatin. Clinical and Translational Oncology, 2018, 20, 500-507.	2.4	3
158	Protocolo de un dÃa vs protocolo de dos dÃas de adquisiciÃ³n mediante gammagrafÃa con leucocitos marcados in vitro para el diagnÃ³stico de infecciÃ³n osteoarticular. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2018, 37, 277-284.	0.0	3
159	Identification of immunosuppressive factors in retinoblastoma cell secretomes and aqueous humor from patients. Journal of Pathology, 2022, , .	4.5	3
160	Correspondence on "G-CSF as a suitable alternative to GM-CSF to boost dinutuximab-mediated neutrophil cytotoxicity in neuroblastoma treatment" by Martinez Sanz et al. , 2021, 9, e003751.		2
161	Upfront Nephrectomy for the Treatment of Wilms Tumor: Outcomes and Predictors of Complications. Journal of Child Science, 2018, 08, e21-e26.	0.2	1
162	GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).. Journal of Clinical Oncology, 2021, 39, 11529-11529.	1.6	1

#	Article	IF	Citations
163	N7: A novel multiâ€modality therapy of high risk neuroblastoma (NB) in children diagnosed over 1 year of age. Medical and Pediatric Oncology, 2001, 36, 227-230.	1.0	1
164	AC-265347 Inhibits Neuroblastoma Tumor Growth by Induction of Differentiation without Causing Hypocalcemia. International Journal of Molecular Sciences, 2022, 23, 4323.	4.1	1
165	Molecular pathways linking the pheochromocytoma susceptibility genesâ€"response. Pediatric Blood and Cancer, 2007, 49, 1052-1053.	1.5	0
166	Results of the survey about the use of the SPECT-CT in bone pathology in Spain during 2012. Medecine Nucleaire, 2015, 39, 444-449.	0.2	0
167	Hipoestesia mentoniana como manifestaciÃ³n de metÃ¡stasis mandibular diagnosticada en la gammagrafÂa Ã³sea. Revista Espanola De Medicina Nuclear E Imagen Molecular, 2016, 35, 34-37.	0.0	0
168	Tissue sampling in diffuse intrinsic pontine glioma (DIPG) at progression. Pediatric Blood and Cancer, 2017, 64, e26492.	1.5	0
169	Editorial: Proceedings From the 4th Memorial Alicia Pueyo Workshop: â€œMoving Towards a Cure for Diffuse Intrinsic Pontine Gliomaâ€. Frontiers in Oncology, 2019, 9, 42.	2.8	0
170	Functional Common and Rare ERBB2 Germline Variants Cooperate in Familial and Sporadic Cancer Susceptibility. Cancer Prevention Research, 2021, 14, 441-454.	1.5	0